Medivation Announces Conference Call and Webcast Providing Detailed Review of Talazoparib

SAN FRANCISCO, CA--(Marketwired - July 01, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will host an investor conference call and live audio webcast on Wednesday, July 6, 2016 at 4:30 p.m. Eastern Time to provide a detailed review of its promising and potentially best-in-class PARP inhibitor talazoparib.

Interested parties may access the live audio webcast and presentation materials by visiting the Investors section of the company's website at http://investors.medivation.com/events.cfm. Please connect to the website 10 minutes prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

Conference Call Details:

• U.S. Dial-in number: 877-303-2523
• International Dial-in number: [phone]
• Conference ID: 43737965

Following the live event, a replay of the audio webcast and presentation materials will be available for at least 30 days on the Investors section of the company's website at http://investors.medivation.com/events.cfm.

About Medivation, Inc.
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com

Contact:
Anne Bowdidge
[phone]